CAR-T cell treatment of CNS Autoimmunity

CAR-T细胞治疗中枢神经系统自身免疫

基本信息

  • 批准号:
    10539779
  • 负责人:
  • 金额:
    $ 67.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-13 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY An immense need for selective and antigen-specific immunotherapy without global immunosuppression exists for autoimmune diseases such as multiple sclerosis (MS) and a closely related condition known as myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD). This has prompted exploration of chimeric antigen receptor (CAR) T cell utilization to specifically eliminate autoreactive cells. We have created a unique version of CAR T cells in which peptide MHCII (pMHCII) was fused with signaling domains in order to recognize specific T cell receptors (TCRs). In preliminary studies we demonstrate that these pMHCII-CAR T cells specifically recognize a cognate TCR in vitro and can selectively kill antigen-specific CD4 T cells in vivo. Efficient depletion of high affinity MOG-specific CD4 T cells was associated with prevention of MOG-induced experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Modifications in pMHCII-CAR construction led to greater efficiency in eliminating lower-affinity MOG-reactive T cells which was associated with resolution of ongoing EAE. These data suggest an “activation energy” model of autoimmunity analogous to that of a chemical reaction, in which higher affinity self-reactive T cells are needed to provide the activation energy to initiate autoimmunity, but lower affinity T cells are capable of sustaining the autoimmune “reaction.” To address the hypothesis that CAR T cell technology can be used to eliminate auto-antigen-specific T cells and abrogate central nervous system (CNS) autoimmunity in mice and humans without global immunosuppression, we have formulated three specific aims. In Aim 1 we will improve the efficiency of low affinity T cell deletion in vivo. In Aim 2, we will test whether we can successfully target autoreactive CD4 T cells specific to all T cell epitopes of a protein in mice, as we predict that such an approach would be useful for treatment of human disease where the T cell autoantigen is identified by an autoantibody. Finally, in Aim 3, we will directly test whether MOGAD patients show an increased frequency of MOG-specific T cells using pMHCII-CARs for antigen discovery. In sum, our proposed studies will explore the “activation energy” model of autoimmunity and establish an optimal CAR T cell approach to eliminate low affinity autoreactive TCR specificities for the treatment of ongoing autoimmune disease. Finally, we will begin to translate these murine observations to human pMHCII-CAR T cells and assess their potential utility in a relevant human autoimmune CNS disease.
项目总结 在没有全球免疫抑制的情况下,存在着对选择性和抗原特异性免疫治疗的巨大需求 用于自身免疫性疾病,如多发性硬化症(MS)和一种密切相关的疾病,称为髓鞘 少突胶质细胞糖蛋白(MOG)抗体病(MOGAD)。这促使人们探索嵌合体 利用抗原受体(CAR)T细胞来特异性地消除自身反应细胞。我们创造了一个独特的 CAR T细胞的一种形式,其中多肽MHCII(PMHCII)与信号域融合以识别 特异性T细胞受体(TCR)。在初步研究中,我们证明了这些pMHCII-CAR T细胞 在体外特异性识别同源TCR,在体内选择性杀伤抗原特异性CD4T细胞。高效 耗尽高亲和力MOG特异性CD4T细胞与预防MOG诱导的实验性 自身免疫性脑脊髓炎(EAE)是MS的动物模型,对pMHCII-CAR结构的修改导致了 更有效地清除低亲和力的MOG反应性T细胞,这与解决 正在进行的EAE。这些数据表明,自身免疫的“激活能”模型类似于化学物质。 反应,在这个反应中,需要更高亲和力的自我反应性T细胞来提供启动 自身免疫,但亲和力较低的T细胞能够维持自身免疫的“反应”。要解决这个问题 假设CAR T细胞技术可以用来消除自身抗原特异的T细胞和清除中央 没有全球免疫抑制的小鼠和人类神经系统(CNS)自身免疫,我们有 制定了三个具体目标。在目标1中,我们将提高体内低亲和力T细胞的删除效率。在AIM 2,我们将测试我们是否能够成功地靶向针对A组T细胞表位的自体反应性CD4T细胞 蛋白质,因为我们预测这种方法将用于治疗人类疾病,其中 T细胞自身抗原是由自身抗体识别的。最后,在目标3中,我们将直接测试MOGAD患者 显示使用pMHCII-CARS发现抗原的MOG特异性T细胞的频率增加。总而言之,我们的 拟议的研究将探索自身免疫的“激活能”模型,并建立一个最佳的CAR T细胞 用于治疗持续自身免疫性疾病的消除低亲和力自身反应性TCR特异性的方法。 最后,我们将开始将这些小鼠的观察结果转化为人类pMHCII-CAR T细胞,并评估它们的 在相关的人类自身免疫性中枢神经系统疾病中的潜在效用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHYI S HSIEH其他文献

CHYI S HSIEH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHYI S HSIEH', 18)}}的其他基金

CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
  • 批准号:
    10641913
  • 财政年份:
    2022
  • 资助金额:
    $ 67.19万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10514950
  • 财政年份:
    2022
  • 资助金额:
    $ 67.19万
  • 项目类别:
Immune interactions with commensal microbes in early life
生命早期与共生微生物的免疫相互作用
  • 批准号:
    10567936
  • 财政年份:
    2022
  • 资助金额:
    $ 67.19万
  • 项目类别:
B cell-targeted CAR-T treatment of CNS Autoimmunity
B细胞靶向CAR-T治疗中枢神经系统自身免疫
  • 批准号:
    10677698
  • 财政年份:
    2022
  • 资助金额:
    $ 67.19万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10614624
  • 财政年份:
    2021
  • 资助金额:
    $ 67.19万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10456984
  • 财政年份:
    2021
  • 资助金额:
    $ 67.19万
  • 项目类别:
Gut Intrinsic Inflammatory Responses
肠道内在炎症反应
  • 批准号:
    10282913
  • 财政年份:
    2021
  • 资助金额:
    $ 67.19万
  • 项目类别:
The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses
细菌抗原进入途径对结肠 T 细胞反应的作用
  • 批准号:
    9912712
  • 财政年份:
    2018
  • 资助金额:
    $ 67.19万
  • 项目类别:
ROLE OF STRESS IN GUT IMMUNE INTERACTIONS WITH COMMENSAL BACTERIA
压力在肠道免疫与共生细菌相互作用中的作用
  • 批准号:
    10204715
  • 财政年份:
    2018
  • 资助金额:
    $ 67.19万
  • 项目类别:
The Role of Route of Entry by Bacterial Antigens on Colonic T Cell Responses
细菌抗原进入途径对结肠 T 细胞反应的作用
  • 批准号:
    10396536
  • 财政年份:
    2018
  • 资助金额:
    $ 67.19万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 67.19万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了